Faculty & Scientific Staff

Jerry Nepom

Gerald Nepom, MD, PhD

Emeritus Member, Center for Interventional Immunology; ITN Senior Advisor
Immune Tolerance Network

Background Information

Dr. Nepom received his bachelor’s degree in Biochemistry from Harvard in 1972 and doctorates from the University of Washington, receiving his PhD in Biochemistry in 1977 and his MD in 1978. After post-doctoral work in immunogenetics in the Department of Pathology at Harvard Medical School, he returned to Seattle, joining the Fred Hutchinson Cancer Research Center and the University of Washington Medical School Faculty in 1982. Since 1985 he has been a Member of the Benaroya Research Institute at Virginia Mason (BRI) and served as Director of BRI from 1985 through 2015. Dr. Nepom also served as Director of the Immune Tolerance Network (ITN), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) from 2010 to 2022. He is currently an Emeritus Faculty Member of BRI and Senior Advisor to ITN.

Area Of Research

Dr. Nepom's interests are focused on identifying and understanding molecular and genetic mechanisms contributing to pathogenesis of autoimmune disorders and using this information to evaluate autoreactive T cell lineage and fate determination. Translational and clinical applications include development and use of immunological monitoring tools for predicting disease susceptibility and response to therapy in clinical trials, with special emphasis on type 1 diabetes.

Related Stories

Blog Main Image - Researcher Woman Bucket Samples
November 30, 2020

One Step Closer to Preventing Celiac Disease

Celiac disease, like all autoimmune diseases, has no cure. People with the condition must adhere to a strict gluten-free diet or face symptoms like nausea, vomiting, ulcers and intestinal damage.

Read Article
Blog Main Image - BRI Researcher Pipetting Samples 2
November 7, 2018

Improving Diabetes Research Worldwide

Type 1 diabetes (T1D) is an immensely complex disease, which means it’s going to take many minds—and many approaches—to conquer it. BRI plays a key role in this fight. Here are three ways we're using our expertise to improve research worldwide.

Read Article
Blog Main Image - Peanut Butter Sandwich
March 8, 2016

Landmark Studies Shows Strides Against Peanut Allergies

A landmark study called LEAP (Learning Early About Peanut Allergy) demonstrated that regular peanut consumption begun in early infancy and continued until age five reduced the rate of peanut allergy in at-risk infants by 80 percent compared to non-peanut consumers.

Read Article


Biological 'atlas' shows dual personality for immune cells that cause type 1 diabetes

Read more ➡
Science in Seattle Logo

A New Clinical Trial on the Treatment of Multiple Sclerosis Starts Enrollment

Read news ➡
News icon

New York Times: New Peanut Allergy Drug Shows 'Lifesaving' Potential

Read news ➡